Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine. It is available as standard oral tablets and orally disintegrating tablets (ODT). ## Primary Indications Acute treatment of migraine attacks with or without aura in adults and pediatric patients. ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg at the onset of migraine symptoms. * **Redosing:** If migraine recurs or the initial dose is ineffective, a second dose may be taken at least 2 hours after the first dose. * **Maximum Dose:** 30 mg within a 24-hour period. ## Pediatric Dosing * **Children 6 to 17 years:** * **Weight < 40 kg:** 5 mg single dose. * **Weight ≥ 40 kg:** 10 mg single dose. * **Redosing:** A second dose may be administered after 2 hours if needed (total daily dose limits apply). Do not exceed 2 doses in 24 hours. ## Dose Adjustments * **Hepatic Impairment:** Use with caution in mild to moderate impairment; use of 5 mg is generally recommended. Avoid in severe impairment. * **Renal Impairment:** Use with caution; 5 mg dose is recommended. * **Concurrent Propranolol Use:** Propranolol increases rizatriptan plasma concentrations. The dose should be limited to 5 mg (maximum of 15 mg in 24 hours). ## Contraindications * History of ischemic heart disease, coronary artery vasospasm (Prinzmetal's angina), or MI. * Uncontrolled hypertension. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease or ischemic bowel disease. * Administration within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. * MAO-A inhibitor use within the past 2 weeks. * Hemiplegic or basilar migraine. ## Adverse Effects * **Common:** Paresthesia, somnolence, dizziness, fatigue, and chest "tightness" or pressure (usually non-cardiac). * **Serious:** Coronary vasospasm, myocardial infarction, arrhythmias, or serotonin syndrome (especially when combined with SSRIs/SNRIs). ## Key Drug Interactions * **MAO-A Inhibitors:** Potentially fatal; strictly contraindicated. * **Propranolol:** Increases rizatriptan exposure significantly; dose reduction is mandatory. * **SSRIs/SNRIs:** Increased risk of serotonin syndrome. Monitor closely for mental status changes, autonomic instability, and neuromuscular abnormalities. ## Monitoring * **Cardiac:** Baseline monitoring for patients with risk factors for coronary artery disease. Consider an ECG for the first dose in high-risk patients. * **Neurological/Sensory:** Monitor for atypical chest, throat, or neck pain indicative of vasospastic events. * **Efficacy:** Monitor for frequency of use to avoid medication-overuse headache. ## Clinical Pearls * **ODT Formulation:** The ODT formulation does not require water; the blister pack should be dry before opening, and the tablet should be placed on the tongue to dissolve. * **Medication-Overuse Headache:** Limit use to no more than 10 days per month to prevent rebound headaches. * **Administration:** Efficacy is highest when taken as soon as pain begins. *** *Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify dosages and contraindications with the official package insert or local institutional protocols before prescribing or administering medication.*